1Fattovich G,Giustina G,Favarato S,et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon.J Hepatol,1996,24(1):38.
2Andrione P,Cursaro C,Gramenzi A.et al.Indomethacin enhances serum 2'5'-oligoademylate synthetase in patients with hepatitis B and C virus chronic active hepatitis, J Hepatol,1994,21(6):984.
3Itoh H,Nakata H,Yokoya Y,et al. Efficacy and side effects of intermittent recombinant interferon-alpha-2a in chronic aggressive hepatitis C:with or without initial daily administration. J Gastroenterol Hepatol,1996,11(8):718.
4Dourakis SP,Deutsch M, Hadziyannis SJ, et al. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol,1996,25(6):972.
5Jacquot C,Caudwell V,Belenfant X. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: Evidence for a synergistic hematologic toxicity.Am J Med,1996,101(2):235.
6Perrillo R,Tamburro C, Regenstein F,et al. Low-dose,titratahle interferon alph in decompensated liver disease caused by chronic infection with hepatitis B virus.Gastroenterology,1995,109(3):908.
7Todros L,Saracco G,Durazzo M.et al. Efficacy and safety of interferon alph therapy in chronic hepatitis C with autoantibodies to liver kidney microsomes. Hepatology,1995,22:1374.
8Janssen HL,Brouwer JT,Van Der Mast RC.et al.Suicide associated with alph-interferon therapy for chronic viral hepatitis, J Hepato1,1994,21 (2):241.
